Analysts are on the Bearish side about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) this week.

January 22, 2018 - By Ellis Scott

 Analysts are on the Bearish side about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) this week.
Investors sentiment increased to 2.21 in Q3 2017. Its up 0.90, from 1.31 in 2017Q2. It improved, as 10 investors sold Tetraphase Pharmaceuticals, Inc. shares while 14 reduced holdings. 19 funds opened positions while 34 raised stakes. 29.38 million shares or 42.90% more from 20.56 million shares in 2017Q2 were reported.
Gp One Trading Lp owns 121,364 shares for 0.01% of their portfolio. State Of Wisconsin Inv Board, Wisconsin-based fund reported 28,000 shares. Wellington Management Llp owns 1.69 million shares for 0% of their portfolio. Credit Suisse Ag reported 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Sg Americas Secs Llc invested in 15,608 shares or 0% of the stock. Canada Pension Plan Inv Board holds 0.04% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 2.55M shares. Axa has invested 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). California Employees Retirement Systems reported 242,200 shares. Dow De reported 0.11% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Moreover, Deutsche State Bank Ag has 0% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 82,429 shares. Cap Fund Mgmt reported 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Millennium Management Llc owns 0.02% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 2.08 million shares. 42,362 were accumulated by Nationwide Fund Advsr. Metropolitan Life Insur Commerce New York stated it has 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Renaissance Tech Ltd Liability Corp stated it has 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH).

Since August 17, 2017, it had 0 buys, and 3 selling transactions for $191,435 activity.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Among 13 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 38% are positive. Tetraphase Pharmaceuticals had 25 analyst reports since August 6, 2015 according to SRatingsIntel. JMP Securities downgraded Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Wednesday, September 9 to “Market Perform” rating. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Hold” rating by Needham on Friday, September 15. The rating was downgraded by Robert W. Baird on Wednesday, September 9 to “Neutral”. As per Thursday, November 19, the company rating was upgraded by SunTrust. On Thursday, October 5 the stock rating was maintained by BMO Capital Markets with “Outperform”. BMO Capital Markets maintained it with “Buy” rating and $11.7600 target in Wednesday, June 21 report. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, September 9. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Hold” rating given on Wednesday, September 9 by Brean Capital. The firm earned “Hold” rating on Wednesday, September 9 by Cantor Fitzgerald. Gabelli downgraded Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) on Friday, May 13 to “Neutral” rating. Below is a list of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) latest ratings and price target changes.

05/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $13 New Target: $24 Maintain
15/09/2017 Broker: Needham Rating: Hold Maintain
11/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $13.0 Maintain
28/08/2017 Broker: PiperJaffray Rating: Overweight New Target: $14 Initiates Coverage On
03/08/2017 Broker: Needham Rating: Hold Maintain
26/07/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $6.9 New Target: $13 Maintain
26/07/2017 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade

The stock increased 2.37% or $0.15 during the last trading session, reaching $6.49. About 152,305 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since January 22, 2017 and is uptrending. It has outperformed by 89.88% the S&P500.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $333.68 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

More notable recent Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were published by: Globenewswire.com which released: “Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in …” on December 06, 2017, also Globenewswire.com with their article: “Tetraphase Pharmaceuticals to Present Data at IDWeek 2017” published on September 25, 2017, Fool.com published: “Why Tetraphase Pharmaceuticals Fell 11.7% Today” on July 27, 2017. More interesting news about Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) were released by: Prnewswire.com and their article: “Technical Perspectives on pSivida, Tetraphase Pharma, Lannett, and Catalent” published on January 02, 2018 as well as Globenewswire.com‘s news article titled: “Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer” with publication date: October 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: